Skip to content

The Anabolic Properties of a Lipid-rich Pork Matrix

The Anabolic Properties of a Lipid-rich Pork Matrix

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05876299
Enrollment
16
Registered
2023-05-25
Start date
2023-07-15
Completion date
2024-04-09
Last updated
2025-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Protein Synthesis

Brief summary

The amount and quality of skeletal muscle mass determines physical performance, but also a significant contributor to metabolic health. As such, the maintenance of skeletal muscle mass is relevant across the lifespan to remain active in family and community life. Food ingestion, particularly protein, is one of the main anabolic to skeletal muscle tissue by stimulating muscle protein synthesis rates. There have been multiple attempts to identify specialized performance nutrition products (e.g., various isolated protein powders) to maximize the anabolic properties of dietary protein on muscle. Our research group, however, has advocated for a food focus approach to meet dietary protein requirements. Particularly, we propose that whole foods demonstrate food matrix effects (nutrient-nutrient interactions) that creates a greater anabolic action on muscle beyond what amino acids can create alone. Therefore, the objective of this study is to identify the anabolic properties of consuming lipid-rich pork products when compared to their leaner counter-parts. Our working hypothesis that the ingestion of 84% or 96% lean ground pork condition will stimulate a greater increase in muscle protein synthesis rates compared to an isocaloric carbohydrate beverage in healthy adults. We further hypothesize that the ingestion of 84% lean pork will augment the stimulation of muscle protein synthesis rates to a greater extent than 96% lean ground pork. To achieve our objective, we will recruit 15 healthy men and women (20-50 y) to receive prime-constant infusions to directly measure muscle protein synthesis rates before and after treatment ingestion using our lab's established methods.

Interventions

OTHER81.16% Lean Pork

This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.

OTHER95.1% Lean Pork

This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.

This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.

Sponsors

University of Illinois at Urbana-Champaign
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This study will employ a semi-crossover model whereby participants will complete 2 of 3 conditions, each.

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 20-50 yrs * Pre-menopausal * Recreationally active * Weight stable for prior 6 months

Exclusion criteria

* Age outside of range (20 - 50 yrs) * Pregnancy * Irregular menstrual cycles * Participation in previous research using \[13C6\]phenylalanine * Participation in other ongoing research that interferes with this study (e.g., conflicting diet, activity interventions, etc.) * Any hospitalization or surgery for a metabolic, cardiovascular, or neuromusculoskeletal complication within the past year * Allergy or hypersensitivity to local anesthetics, latex, or adhesives (bandages, medical tape, etc.) * Excess scarring after injury * History of excess bleeding after cut * Chronic or frequent dizziness/fainting, and arm or leg weakness/numbness * Arthritis * Tumors * Mental Illness * Hepatorenal, cardiovascular musculoskeletal, autoimmune, or neurological disease or disorder * Predisposition to hypertrophic scarring or keloid formation * Physical activity limitations * Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation * Consumption of thyroid, androgenic, or other medications known to affect endocrine function * Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication) * Unwillingness to comply with study procedures * Weight unstable (variation \>5% of bodyweight in last 6-12 months) * Current or previous tobacco use with last 6 months * Obesity (body mass index; BMI \> 30 kg/m\^2) * Score of less than 14 or greater than 24 on Godin-Shephard Leisure-Time Physical Activity Questionnaire * Phenylketonuria * Anyone hospitalized previously for COVID-19 without a cardiovascular workup screening for cardiovascular issues post-infection * Anyone recovering from COVID-19 infection within the preceding 10 days

Design outcomes

Primary

MeasureTime frameDescription
Myofibrillar Fractional Synthetic RateDuring 5-hour post-prandial period following consumption of the study meal or beverageRate of building new protein in skeletal muscle contractile protein

Secondary

MeasureTime frameDescription
Plasma Amino Acid ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestionConcentration of amino acids in plasma as determined by LC/MS/MS
Plasma Free Fatty Acid ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestionConcentration of amino acids in plasma as determined by GC-MS
Plasma Insulin ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestionConcentration of insulin in plasma as determined by commercially-available ELISA kits
Plasma Glucose ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestionConcentration of glucose in plasma as determined by an automated biochemistry analyzer (YSI)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026